Physician profile
Daniel Harris
NPI 1831149210
$2,935.27
in general payments reported to CMS, 2019-2025
21 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $303 · 2021: $614 · 2022: $422 · 2023: $475 · 2024: $589 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Education: $15.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.84 |
| Education | $15.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $971.99 | 2019-2025 | |
| Ucb, INC. | $515.43 | 2019-2025 | Bimzelx |
| Abbvie INC. | $340.01 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $210.32 | 2021-2024 | Odomzo, Blu-U |
| Sensus Healthcare, INC. | $178.57 | 2019-2020 | |
| Lilly USA, LLC | $144.84 | 2019-2023 | Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $92.91 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $66.53 | 2020-2023 | Dupixent |
| Amgen INC. | $62.42 | 2021-2024 | Otezla |
| Janssen Biotech, INC. | $54.90 | 2020-2022 | |
| Dusa Pharmaceuticals, INC. | $47.45 | 2019 | |
| Genzyme Corporation | $44.71 | 2021-2022 | |
| Pfizer INC. | $38.05 | 2019 | |
| Krystal Biotech INC | $33.26 | 2024 | Vyjuvek |
| Leo Pharma INC. | $29.84 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.76 | 2020 | |
| Nabriva Therapeutics, Plc | $19.34 | 2022 | |
| Organogenesis INC. | $18.83 | 2023 | Puraply |
| Incyte Corporation | $15.26 | 2023 | Opzelura |
| Dermira, INC. | $14.51 | 2020 | |
| Genentech USA, INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.